InvestorWire NewsRoom


InvestorNewsBreaks – Apollomics Inc. (NASDAQ: APLM) Closes on Business Combination, Begins Trading
March 31, 2023

InvestorNewsBreaks – Apollomics Inc. (NASDAQ: APLM) Closes on Business Combination, Begins Trading

Apollomics (NASDAQ: APLM), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, has completed its business combination with Maxpro Capital Acquisition Corp. (NASDAQ: JMAC). According to the announcement, the company anticipated its class A ordinary shares and public warrants to commence trading on March 30, 2023, on the Nasdaq Capital Market. Apollomics is committed to improve treatment options for patients diagnosed with difficult-to-treat, high- mortality cancers. “Becoming a public company represents a major milestone in our journey to provide solutions for patients with difficult-to-treat cancers worldwide,” said Apollomics chair and CEO Dr. Guo-Liang Yu, PhD, in the press release. “The funds now available to us are expected to facilitate development of our oncology pipeline and further our mission to provide patients with effective therapies and hope.”

To view the full press release, visit

About Apollomics Inc.

Apollomics is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics currently has a pipeline of nine drug candidates across multiple programs, six of which are currently in the clinical stage of development. Apollomics’ lead programs include investigating its core product, vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a phase 2 multicohort clinical trial in the United States, and developing an anticancer enhancer drug candidate, uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia and other hematologic cancers, which is currently in phase 1 and phase 3 clinical trials in China. For more information about the company, please visit

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
[email protected]

InvestorWire is part of the InvestorBrandNetwork

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).